SHSE:688105 (China)
Â
Class A
Â¥
16.88
-0.060 (-0.35%)
Jul 24
Business Description
Nanjing Vazyme Biotech Co Ltd
ISIN : CNE100004ZK3
Share Class Description:
SHSE:688105: Class ATotal Employee Number:
3,002Compare
Compare
Traded in other countries / regions
688105.China Index Membership
SSE Composite IndexCSI 500 Index IPO Date
2021-11-15Description
Nanjing Vazyme Biotech Co Ltd is a biotechnology company. It is committed to research and development both in technology and products focusing on functional proteins, such as enzymes, antigens, antibodies, and polymer organic materials.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.92 | |||||
Equity-to-Asset | 0.75 | |||||
Debt-to-Equity | 0.27 | |||||
Debt-to-EBITDA | -71.43 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 5.14 | |||||
Beneish M-Score | -2.71 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -28.2 | |||||
3-Year EBITDA Growth Rate | -43.9 | |||||
3-Year Book Growth Rate | -6.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 20.15 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 37.35 | |||||
9-Day RSI | 45.36 | |||||
14-Day RSI | 49.44 | |||||
3-1 Month Momentum % | 14.16 | |||||
6-1 Month Momentum % | -0.37 | |||||
12-1 Month Momentum % | -11.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.39 | |||||
Quick Ratio | 3.08 | |||||
Cash Ratio | 2.61 | |||||
Days Inventory | 314.99 | |||||
Days Sales Outstanding | 122.67 | |||||
Days Payable | 66.99 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 2.96 | |||||
3-Year Dividend Growth Rate | -20.7 | |||||
Forward Dividend Yield % | 2.96 | |||||
5-Year Yield-on-Cost % | 2.95 | |||||
3-Year Average Share Buyback Ratio | 0.2 | |||||
Shareholder Yield % | 1.15 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 69.91 | |||||
Operating Margin % | -1.65 | |||||
Net Margin % | -1.02 | |||||
EBITDA Margin % | -1 | |||||
FCF Margin % | 11.87 | |||||
OCF Margin % | 14.83 | |||||
ROE % | -0.37 | |||||
ROA % | -0.28 | |||||
ROIC % | -0.62 | |||||
3-Year ROIIC % | 3553.81 | |||||
ROC (Joel Greenblatt) % | -1.1 | |||||
ROCE % | -0.35 | |||||
Years of Profitability over Past 10-Year | 6 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 71.83 | |||||
PS Ratio | 5.39 | |||||
PB Ratio | 2.3 | |||||
Price-to-Tangible-Book | 2.43 | |||||
Price-to-Free-Cash-Flow | 43.75 | |||||
Price-to-Operating-Cash-Flow | 35.21 | |||||
EV-to-EBIT | -478.98 | |||||
EV-to-EBITDA | -478.98 | |||||
EV-to-Revenue | 4.78 | |||||
EV-to-FCF | 40.25 | |||||
Price-to-GF-Value | 0.95 | |||||
Price-to-Projected-FCF | 2.1 | |||||
| Price-to-Net-Current-Asset-Value | 3.47 | |||||
| Price-to-Net-Cash | 5.32 | |||||
Earnings Yield (Greenblatt) % | -0.21 | |||||
FCF Yield % | 1.92 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nanjing Vazyme Biotech Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 1,413.549 | ||
| EPS (TTM) (Â¥) | -0.025 | ||
| Beta | 1.376 | ||
| 3-Year Sharpe Ratio | -0.17 | ||
| 3-Year Sortino Ratio | -0.23 | ||
| Volatility % | 30.48 | ||
| 14-Day RSI | 49.44 | ||
| 14-Day ATR (Â¥) | 1.209655 | ||
| 20-Day SMA (Â¥) | 17.641 | ||
| 12-1 Month Momentum % | -11.62 | ||
| 52-Week Range (Â¥) | 12.89 - 20.78 | ||
| Shares Outstanding (Mil) | 516.99 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nanjing Vazyme Biotech Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nanjing Vazyme Biotech Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| CNY 0.500000 Cash Dividend | 2026-06-03 | 14.45 (-2.49%) | ||
| 1.3:1 Stock Split | 2026-06-03 | 14.45 (-2.49%) | ||
| CNY 0.115385 Cash Dividend | 2025-06-05 | 17.55 (-0.87%) | ||
| CNY 0.023077 Cash Dividend | 2024-12-20 | 18.13 (+0.68%) |
Show
Entries
Nanjing Vazyme Biotech Co Ltd Frequently Asked Questions
What is Nanjing Vazyme Biotech Co Ltd(SHSE:688105)'s stock price today?
The current price of SHSE:688105 is ¥16.88. The 52 week high of SHSE:688105 is ¥20.78 and 52 week low is ¥12.89.
When is next earnings date of Nanjing Vazyme Biotech Co Ltd(SHSE:688105)?
The next earnings date of Nanjing Vazyme Biotech Co Ltd(SHSE:688105) is .
Does Nanjing Vazyme Biotech Co Ltd(SHSE:688105) pay dividends? If so, how much?
The Dividend Yield %  of Nanjing Vazyme Biotech Co Ltd(SHSE:688105) is 2.96% (As of Today), Highest Dividend Payout Ratio of Nanjing Vazyme Biotech Co Ltd(SHSE:688105) was 0.2. The lowest was 0.2. And the median was 0.2. The  Forward Dividend Yield % of Nanjing Vazyme Biotech Co Ltd(SHSE:688105) is 2.96%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on Nanjing Vazyme Biotech Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers